A new era in prostate cancer therapy: New targets and novel therapeutics

Deborah A. Bradley, Maha Hussain, Cora N. Sternberg*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The results of two phase III trials demonstrating a significant prolongation of survival with docetaxel-based chemotherapy has fueled interest in expanding therapeutic development in prostate cancer. This coupled with improved understanding of the mechanisms responsible for prostate cancer development and progression has lead to discovery of several biologic targets that can be exploited using novel therapeutics in what has been referred to as the era of "targeted therapy." Several of these therapies have shown promise either as single agents or in combination with proven chemotherapeutic agents. This review focuses upon some of the more promising targeted therapies under investigation for the treatment of hormone refractory prostate cancer and highlights some of challenges faced in therapeutic development.

Original languageEnglish (US)
Pages (from-to)31-39
Number of pages9
JournalTargeted Oncology
Issue number1
StatePublished - Jan 2008


  • Chemotherapy
  • Hormone refractory prostate cancer
  • Metastatic
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A new era in prostate cancer therapy: New targets and novel therapeutics'. Together they form a unique fingerprint.

Cite this